Sandra Disse

🌟 Proud Moment for Localized Healthcare in Saudi Arabia! 🌟 I’m excited to share a significant step forward in advancing healthcare in the Kingdom. Sudair Pharmaceutical Company, in collaboration with Sanofi & National Unified Procurement Company "NUPCO" is making strides towards localizing #Insulin production in Saudi Arabia. This initiative isn’t just about meeting the growing demand for insulin in the region but about creating a robust, sustainable supply chain that caters to our unique healthcare landscape. By fostering local production, we aim to: • Ensure reliable access to life-saving insulin for patients across the Kingdom. • Reduce dependency on international supply chains. • Support national goals outlined in Saudi Vision 2030 to enhance self-sufficiency and localize essential industries. This collaboration is a testament to our shared commitment to empowering healthcare, uplifting our economy, and, most importantly, serving the people of Saudi Arabia. Stay tuned as we continue to make healthcare history together! 💪🌍 #Insulin #SaudiVision2030 #SudairPharma #Sanofi

٣٠٤

١٠ تعليق

The strategic partnership between STADA Group and ADCANPharma aims to enhance access to high-quality medicines in the UAE by leveraging STADA’s #marketexpertise and ADCAN’s #localmanufacturing capabilities. This collaboration allows STADA to expand its product offerings with ADCAN’s #portfolio, including #innovativehealthcareproducts and #prescriptionmedicines. ADCAN’s advanced #AbuDhabi facility ensures a reliable supply, while the combined expertise strengthens their #marketposition and drives growth in the #MENAregion. #Pharmaceuticals #Healthcare #Partnership #STADA #ADCANPharma #ConsumerHealthcare #OTC #Marketing #Collaboration #Manufacturing #MakeinUAE #UAEHealthcareVision #Strategy #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

٢

Hope for those battling Huntington's disease (HD) in the MENA region! IROS CRO, Prilenia, and the #InternationalHuntingtonDiseaseAssociation are launching the first-ever #clinicaltrial for HD in the region. This trial aims to raise #awareness, provide #access to #treatment, and gather crucial #data. Huntington's disease is a #rare, progressive #neurodegenerativedisorder causing #abnormalmovements, #psychiatric issues, and #cognitive decline. This trial brings hope to patients with a new treatment, #pridopidine. Let's spread the word and support this groundbreaking collaboration! #HuntingtonsDisease #MENAHealthcare #PharmaceuticalInnovation #Prilenia #MENA

٢

M&A in the MENA Pharma Market: A Complex Landscape Despite high growth potential, the MENA pharma market remains a challenging environment for M&A. Inflated valuations, deep market nuances, and government protectionism continue to hinder successful deals. While the region has seen notable acquisitions like Sanofi's purchase of UAE-based Global Pharma and Valeant's acquisition of UAE-based Medpharma in 2014, these examples also highlight the complexities involved. It's clear that a deep understanding of local dynamics and a long-term perspective are crucial for success. While PE firms remain active, the path to a profitable M&A deal is still fraught with challenges. What are your thoughts on the MENA pharma M&A landscape? Share your insights and experiences below. #MENApharma #M&A #pharmaindustry #pharmabusiness #challenges #investment #PE

٣

As a mother of 3, this week's topic is very close to my heart: Childhood and Adolescent Obesity... Shedding light on a growing problem (growing twice as fast in children than in adults), especially in our part of the world: according to the World Obesity Atlas 2023, 1 out of 5 adolescents in UAE lives with Obesity and this number will be 1 out of 4 by 2035. By addressing the root causes of Obesity, understanding the consequences, intervening early and implementing effective solutions, we can strive to build a healthier future for the UAE's younger generations. Watch this podcast produced by Khaleej Times, sponsored by Novo Nordisk and endorsed by Emirates Medical Association https://lnkd.in/djydtsVa

٧٢

١ تعليق واحد

🌟 Excited to announce the upcoming ASMA | Annual Summit on Medical Affairs conference that Pfizer Div Khetia, PharmD, MBA are chairing where we'll delve into the latest trends shaping the future of medical affairs in the pharmaceutical industry! 💻 From embracing data and analytics to transforming medical leadership, the landscape is evolving at an unprecedented pace. 🏢 Join us as we explore the impact of #digitaltechnology and #collaborativepartnerships on the #strategicrole of #medicalaffairs. 🎇 Together, we'll navigate the nuances of talent development and the critical need for innovation in this dynamic space. 💡Don't miss this opportunity to gain insights and network with industry leaders at the forefront of redefining medical affairs in pharma, including the following: Carolyn Reever, Ph.D Varun Nagpal, PhD Dylan S.. Peter Gin-Fu Chen, PhD Veruska Sena Savita Nandal, MD Ami Bhatt, MD Bhaskar Dutta Arta Subagiarta, MD, MMSc Shashi Adsul Peter Covitz Stephanie Otis, PharmD CHC Dr Xongi Phaleng Tom Caravela Thomas Yang, PhD Vivek Mukhatyar Sandra Nagale, Ph.D. Hahn-Ey Lee MD, PhD, MBA Ann Westra Chippen Zhao Chathuri Daluwatte, PhD Roberto Araujo 🔗 Register here at https://lnkd.in/dEYgkzDJ! See you at the conference! #MedicalAffairs #PharmaceuticalIndustry #FutureTrends #ConferenceDiscussion 🚀

٣٢

١ تعليق واحد

This is a very interesting article on Saudi Arabia's significant strides toward becoming a regional hub for clinical trials, thanks to its robust infrastructure, favorable regulations, and strategic initiatives to attract global pharma. DISTILL has its HQ in Dubai and is very present in the MENA region. Our platform is well designed to streamline clinical trials, making data management efficient and secure, which is crucial for meeting the evolving regulatory standards and fostering innovation in clinical research. Ping me to know more about DISTILL EDC.   For further insights, read the full article here: https://lnkd.in/g5JGfsAP

٥

🚀🔥 Exciting news from Basel Al-Qahtani and Boston Scientific KSA ! The expansion is REAL and here's what you need to know: 🌟 Milestones Achieved: Boston Scientific establishes a regional HQ in Saudi Arabia, fully committing to Vision 2030 and enhancing patient care pathways. 👉 Quote: "We transitioned from device providers to trusted partners in patient care." - Basel Al-Qahtani 💡 Key Lessons: Transitioning to direct operations requires clear communication and mutual benefit for all parties involved. 🌐 Medtech Trends: Saudi's healthcare sector is booming, with a focus on value-based care and innovative solutions. @bostonsciSaudiArabia leads the charge! 🔍 Market Access: emphasis on healthcare technology assessment (HTA) for top-quality procurement decisions. #HealthcareInnovation #Vision2030 #MedTech #BostonScientific

١٤

We're excited to reveal the keynote speaker for our NUB 4th Scientific Conference, "Health care- Egypt Vision 2030." Please join us in welcoming Dr. Sherif Kamal, Advisor to chairman of Egypt Healthcare Authority, and General Supervisor for Medication management and Pharmacy Affairs. who will share their insights on [Value based Healthcare]. Don't miss this opportunity to hear from a leading expert in the field!" Dr. Sherif Kamal is one of a second generation Egyptian clinical pharmacists, with more than 20 years of experience in this field, involved in the planning, designing and implementation of pharmaceutical care in oncology centers as senior Clinical Pharmacy consultant. Sherif Kamal is the Director of Pharmaceutical Services and clinical Pharmacy program director at the Children's Cancer Hospital in Egypt. He is also a Clinical Pharmacy Consultant at Cairo University and Sina University. He earned his BS in Pharmacy, an MSc in Clinical Pharmacy and is currently a PhD candidate at the Cairo University School of Pharmacy. Sherif has also completed a visiting fellowship at St. Jude's Children Hospital in the United States in 2008. For more than 20 years, Sherif has led a team that implemented clinical pharmacy services at various hospitals throughout Egypt. He is the recipient the Egyptian Hospital Pharmacist Association Award and founder of the Egyptian Association of Clinical Pharmacists in 2010. He is a member of several international organization including the International Society for Oncology Pharmacists, the European Society of Clinical Pharmacy, the American Society of Health-System Pharmacist and the American College of Pharmacy. He has conducted a wide variety of research studies involving the pharmacotherapeutics management of pediatric oncology diseases and presented his work at international meetings (35 poster presentations accepted and two papers titled Study of Valproic acid use in pediatric oncology setting in Egypt 2014). one In addition, Sherif lectures in various courses at Faculty of Pharmacy, Cairo University and Sina Uiversity, Egypt, on pediatric oncology-related topics. His primary research interest focuses on pharmacy practice, patient safety, pharmacogentics, pharmacoeconomics, ppharmacy informatics,harmacovigilance and the pharmaco-epidemiology of pediatric cancer. Sherif is also a professionally and practically qualified project manager in fund raising and business development, with more than seven years experience in this field involved in the fundraising activity of the National Cancer Institute and Children Cancer Hospital Foundation 57357. He is a Certified Lean six sigma green belt -BEC / Quality America Cssbb Candidate - ASQ. "Mark your calendars and join us for this exciting event." #NUB4thScientificConference #HealthcareEgypt2030 #EgyptVision2030 #ScientificConference #NUBUniversity #FacultyofPharmacy #MedicalResearch

٢

How can we make progress towards tackling one of the world's leading causes of death that so many have never heard of? (Personally close to my heart with family members) At AstraZeneca, we believe the solution towards improving chronic obstructive respiratory disease (COPD) care lies in collaboration and raising awareness. That’s why we are working with our industry partners, clinicians, policymakers and patient advocates to bring COPD centre stage in the public health conversation and eliminate it as a leading cause of death. Learn more about how you can #SpeakUpForCOPD and be part of elevating COPD as a public health priority:

١٢

٢ تعليق

We can supercharge progress for patients when public health goals align with private sector priorities. Our partnership in Egypt to accelerate screening for patients with liver #cancer, the leading cause of cancer death in the region, is a prime example of partnership at its best.     When I talk about our ambition at AstraZeneca to eliminate cancer as a cause of death, it’s not just about delivering great science. As you’ve probably heard me say, partnerships are a critical part of our strategy to improve outcomes for patients with cancer. #MIHealthSummit #PowerofIdeas https://lnkd.in/g3FBy4hR

١٨٩

٥ تعليق

At AstraZeneca, we are dedicated to improving patient outcomes for lung cancer by emphasizing early detection. By identifying the disease at its earliest stages, we can implement timely and effective treatments, ultimately enhancing patient quality of life and reducing the long-term burden on healthcare systems. Our commitment to innovative research and advanced diagnostic technologies underscores our mission to transform the future of healthcare. Additionally, in #NearEast and #Maghreb we are actively involved in initiatives such as lung cancer screening via government and patient association collaborations to promote equitable access to cancer care. More into this subject and preventive measures can be found in this article by Independent Arabia https://lnkd.in/ekaXscKe #WorldLungCancerDay #LungCancer #EarlyDetection Peter Raouf Sarah Sakr Khoury Jennifer Jackson George Fouad Jinane Hajjar Amine Sekhri Ayman Rahhal Mohanad Alyas Abdulkareem Al Dissi Maria Nauss

٧٨

Today, marks a significant milestone in our journey towards advancing global #healthcare #innovation! Pfizer Gulf and the Department of Health Abu Dhabi have signed a Memorandum of Understanding (MOU) during the BIO 2024 International Convention at San Diego.   This strategic collaboration aims at enhancing Abu Dhabi’s position as a leading global hub for healthcare, life science, and innovation. Leveraging combined strengths, Pfizer Gulf and the Department of Health Abu Dhabi are committed to advancing research through the generation and analysis of real-world data, initially focusing on Sickle Cell Disease and expanding to other disease areas for the benefit of patients locally, regionally, and beyond.   As we move forward, this partnership will serve as a blueprint for future collaborations towards achieving a shared vision of delivering breakthroughs that change patients’ lives.   #PfizerProud #MOU #DOH #RealWorldData H.E. Mansoor AlMansoori Dr. Asma Al Mannaei

٣٠٩

٤ تعليق

Sandoz has received 𝗺𝗮𝗿𝗸𝗲𝘁𝗶𝗻𝗴 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗳𝗼𝗿 𝗪𝘆𝗼𝘀𝘁® (𝗱𝗲𝗻𝗼𝘀𝘂𝗺𝗮𝗯) 𝗮𝗻𝗱 𝗝𝘂𝗯𝗯𝗼𝗻𝘁𝗶® (𝗱𝗲𝗻𝗼𝘀𝘂𝗺𝗮𝗯), 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘃𝗲𝗿𝘀𝗶𝗼𝗻𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗫𝗴𝗲𝘃𝗮® 𝗮𝗻𝗱 𝗣𝗿𝗼𝗹𝗶𝗮® 𝗶𝗻 𝗘𝘂𝗿𝗼𝗽𝗲. Wyost® is approved for treating cancer-related bone diseases, while Jubbonti® is approved for treating osteoporosis. These approvals mark a significant milestone in Sandoz's growth strategy, with 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗳𝗿𝗼𝗺 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟱. Sandoz's emphasized the importance of these biosimilars in addressing bone loss and cancer-related bone issues, highlighting the need for increased access to these treatments since cancer and osteoporosis pose significant health burdens in Europe. Wyost® is indicated for preventing skeletal-related events in cancer patients and treating unresectable giant cell tumors of bone. Jubbonti® is indicated for treating osteoporosis in postmenopausal women and men at risk of fractures, bone loss from hormone ablation therapy in men with prostate cancer, and bone loss from long-term glucocorticoid therapy in adults at risk of fractures. #marketintelligence #competitiveintelligence #marketsmind #pharmaceutical

٣٥

Do you know the pharmaco-economics requirements in these countries: Algeria, Egypt, Iraq, Jordan, Saudi Arabia, Lebanon, Morocco, Tunisia, and the UAE? Check them out in this article. #pharmacoeconomics #MENA #MarketAccess Market Access Today

٣

In today’s fast-paced healthcare landscape, the integration of data, digital tools, and innovative technologies is transforming the field of medical affairs. By leveraging advanced analytics and artificial intelligence, we can unlock valuable insights that drive better decision-making and enhance patient outcomes. 📊 Data-Driven Decisions: Utilizing real-world evidence allows us to understand patient needs more deeply and tailor our strategies accordingly. This not only improves our engagement with healthcare professionals but also ensures that our communications are relevant and impactful. 💻 Digital Transformation: With the rise of digital platforms, we can connect and collaborate more effectively than ever. Virtual meetings, online training, and digital resources enable us to share knowledge and best practices across teams and geographies, fostering a culture of continuous learning. 🤖 AI in Medical Affairs: The power of AI is revolutionizing how we approach medical communications and research. From predictive analytics to streamline clinical trials, to natural language processing for better data interpretation, AI is helping us to work smarter and faster. As we continue to innovate, let's embrace these technologies to enhance our role in healthcare, drive meaningful change, and ultimately improve patient care. Together, we can shape the future of medical affairs! Please join Div Khetia, PharmD, MBA, Ann Westra, Peter Gin-Fu Chen, PhD, and Chathuri Daluwatte, PhD and me for this important discussion on #innovation in #medicalaffairs! #DataDriven #DigitalHealth #Innovation #MedicalAffairs #AI #HealthcareTransformation

١٩

٦ تعليق

The #PHSSR 3rd Summit was a significant event held during Abu Dhabi Global Healthcare Week, bringing together health system policymakers, experts, and stakeholders worldwide to discuss and enhance global health systems. Key highlights include: 1 - Opening addresses by @AstraZeneca's Chair Michel Demaré and prominent health leaders from Abu Dhabi, Egypt, and Greece. 2 - Launch of the Abu Dhabi PHSSR report with essential policy recommendations on non-communicable diseases and the climate-health nexus. Check out the wrap-up video to learn more about our collective efforts to build resilient health systems. #ADGHW #HealthSystems #GlobalHealth

١٠٢

١ تعليق واحد

The Novo Nordisk Foundation, Wellcome Trust and the Bill & Melinda Gates Foundation have inked a $300 million R&D initiative focused in part on #infectiousdiseases and #antimicrobial resistance. The trio is setting out to tackle several global health challenges, particularly for those that impact more vulnerable populations. The three-year partnership includes a $100 million investment from each party, money that will go toward R&D designed to address the health impacts of #climate change; #infectious diseases; and better understanding the interaction between #nutrition, #immunity, #disease and #developmental outcomes.

١

Reflecting on the incredible sessions and panels at #ESMOGI24, I feel more equipped than ever to tackle the challenges in GI oncology. It was an honor to exchange ideas with the best in the field and witness groundbreaking research unveiling. Here's to transforming insights into impact and forming all the new partnerships. Together, we're moving closer to a world without cancer. #RocheOncology"

٢